Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Circulation Journal

• Publication date

  2015-04-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1253/circj.CJ-15-0319PMID 25833178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

  2015cited by this paper
• Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.

  2015cited by this paper
• Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban

  2015cited by this paper
• 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous

  2014cited by this paper
• Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.

  2014cited by this paper
• Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

  2014cited by this paper
• Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).

  2014cited by this paper
• Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management: Results From the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Rand

  2014cited by this paper
• [2014 ESC/EACTS Guidelines on myocardial revascularization].

  2014cited by this paper
• 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

  2014cited by this paper
• Safety of Continuous Periprocedural Rivaroxaban for Patients Undergoing Left Atrial Catheter Ablation Procedures

  2014cited by this paper
• 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca

  2014cited by this paper
• Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.

  2013cited by this paper
• Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.

  2013cited by this paper
• The role of the laboratory in treatment with new oral anticoagulants

  2013cited by this paper
• European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

  2013cited by this paper
• Dabigatran versus warfarin in patients with mechanical heart valves.

  2013cited by this paper
• Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter

  2013cited by this paper
• "R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation.

  2013cited by this paper
• Edoxaban versus warfarin in patients with atrial fibrillation.

  2013cited by this paper
• Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants

  2013cited by this paper
• Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation

  2013cited by this paper
• Stroke and bleeding in atrial fibrillation with chronic kidney disease.

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial

  2012cited by this paper
• Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association.

  2012cited by this paper
• Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

  2012cited by this paper
• Rivaroxaban in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Bleeding risk assessment and management in atrial fibrillation patients. Key messages for clinical practice from the European Heart Rhythm Association position statement.

  2012cited by this paper
• 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.

  2012cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Corrigendum to: ‘Guidelines for the management of atrial fibrillation’ [European Heart Journal (2010) 31, 2369–2429 and EP-Europace (2010) 12, 1360–1420]

  2011cited by this paper
• Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin.

  2011cited by this paper
• Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk.

  2011cited by this paper
• Bleeding risk assessment and management in atrial fibrillation patients

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion

  2010cited by this paper
• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

  2010cited by this paper
• Arrhythmia recurrence after ablation of atrial fibrillation: should we be concerned about sleep apnoea?

  2010cited by this paper
• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

  2010cited by this paper
• Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Milestones in the management of atrial fibrillation.

  2009cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.

  2006cited by this paper
• Hypercoagulopathy in Stroke Patients with Nonvalvular Atrial Fibrillation: Hematologic and Cardiologic Investigations

  2006cited by this paper
• Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

  2006cited by this paper
• Inflammation in the genesis and perpetuation of atrial fibrillation.

  2005cited by this paper
• Virchow's triad revisited.

  2004cited by this paper
• Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease

  2004cited by this paper
• Is the Hypercoagulable State in Atrial Fibrillation Mediated by Vascular Endothelial Growth Factor?

  2002cited by this paper
• Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study

  2001cited by this paper
• Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities.

  2000cited by this paper
• Assessment of Left Atrial Appendage Structure and Function by Transesophageal Echocardiography

  1998cited by this paper
• Assessment of Left Atrial Appendage Function by Transesophageal Echocardiography: Implications for the Development of Thrombus

  1991cited by this paper

• Management of Cardiac Rhythm Disorders in Cardio-oncology

  2025cites this paper
• Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users.

  2021cites this paper
• Thoracoscopic surgical ablation versus catheter ablation as first-line treatment for long-standing persistent atrial fibrillation: the CASA-AF RCT

  2021cites this paper
• Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots.

  2020cites this paper
• Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF): study protocol for a randomised controlled trial

  2018cites this paper
• Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: A Practical Guide for Neurologists

  2018cites this paper
• Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study

  2017cites this paper
• The Introduction Timing of Oral Anticoagulants in the Early Phase of Acute Stroke Patients

  2017cites this paper
• The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation

  2017cites this paper
• Risk of long-term anticoagulation under sustained severe arterial hypertension: A translational study comparing warfarin and the new oral anticoagulant apixaban

  2017cites this paper
• Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience

  2016influential citation
• Silent Cerebral Ischemic Lesions After Catheter Ablation of Atrial Fibrillation in Patients on 5 Types of Periprocedural Oral Anticoagulation　- Predictors of Diffusion-Weighted Imaging-Positive Lesions and Follow-up Magnetic Resonance Imaging.

  2016cites this paper
• Silent Cerebral Embolism After Catheter Ablation for Atrial Fibrillation　- Unresolved Issue or Too Much Concern?

  2016cites this paper
• Stroke Prevention in Atrial Fibrillation

  2015cites this paper
• Innovative Therapeutics for Atrial Fibrillation: Imminent Breakthroughs or Much Ado About Nothing?

  2015cites this paper